These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20826742)

  • 1. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients.
    Sonnweber T; Theurl I; Seifert M; Schroll A; Eder S; Mayer G; Weiss G
    Nephrol Dial Transplant; 2011 Mar; 26(3):977-87. PubMed ID: 20826742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
    Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
    Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis.
    Kuragano T; Itoh K; Shimonaka Y; Kida A; Furuta M; Kitamura R; Yahiro M; Nanami M; Otaki Y; Hasuike Y; Nonoguchi H; Nakanishi T
    Nephrol Dial Transplant; 2011 Aug; 26(8):2663-7. PubMed ID: 21245128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepcidin and iron deficiency in pre-kidney transplant patients.
    Sancho A; Pastor MC; Troya M; Bonal J; Bayés B; Morales-Indiano C; Lauzurica R; Romero R
    Transplant Proc; 2009; 41(6):2079-81. PubMed ID: 19715836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between circulating electronegative low-density lipoproteins and serum ferritin in hemodialysis patients: a pilot study.
    Lobo JC; Farage NE; Abdalla DS; Velarde LG; Torres JP; Mafra D
    J Ren Nutr; 2012 May; 22(3):350-6. PubMed ID: 21741859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease.
    Ferrari P; Mallon D; Trinder D; Olynyk JK
    Nephrology (Carlton); 2010 Apr; 15(3):344-9. PubMed ID: 20470305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
    Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
    Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
    Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer.
    Yang DC; Wang F; Elliott RL; Head JF
    Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of tumor necrosis factor-α downregulate antimicrobial iron transport protein, Nramp1, in chronic hemodialysis patients: a key factor for infection risk.
    Moriguchi R; Otaki Y; Hazeki S; Shimada T; Matsumoto A; Kakita N; Kaibe S; Kuragano T; Nonoguchi H; Masayoshi N; Hasuike Y; Nakanishi T
    Am J Nephrol; 2012; 35(4):372-8. PubMed ID: 22508410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
    Malyszko J; Malyszko JS; Mysliwiec M
    Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of peripheral blood monocytes in haemodialysis: in vivo induction of tumour necrosis factor alpha, interleukin 6 and beta 2-microglobulin.
    Pertosa G; Marfella C; Tarantino EA; Di Cillo M; Manno C; Russo R; Schena FP
    Nephrol Dial Transplant; 1991; 6 Suppl 2():18-23. PubMed ID: 1866063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepcidin expression in patients with acute leukaemia.
    Cheng PP; Sun ZZ; Jiang F; Tang YT; Jiao XY
    Eur J Clin Invest; 2012 May; 42(5):517-25. PubMed ID: 22023453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional, but not high-purity, dialysate-induced monocyte apoptosis is mediated by activation of PKC-delta and inflammatory factors release.
    Guo LL; Pan Y; Zhu XJ; Tan LY; Xu QJ; Jin HM
    Nephrol Dial Transplant; 2011 May; 26(5):1516-22. PubMed ID: 20923925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease.
    Aigner E; Theurl I; Haufe H; Seifert M; Hohla F; Scharinger L; Stickel F; Mourlane F; Weiss G; Datz C
    Gastroenterology; 2008 Aug; 135(2):680-8. PubMed ID: 18505688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.